Reducing Endocrinopathies of Immune Checkpoint Inhibitor Therapy: Management Strategies for Oncology Pharmacists

Stream Link: https://event.arraylive.com/app/login/72fc59b4-8107-4979-85f1-c949424d0697

A PTCE virtual symposium affiliated with the 2024 HOPA Annual Conference.

Program Description

Immune checkpoint inhibitors (ICIs) have been associated with unique adverse event profiles, the most notable affecting the endocrine system. ICI-associated endocrinopathies can consist of thyroid, pituitary, adrenal gland, and pancreas dysfunction. The effective management of immune-related adverse events (irAEs) depends on early recognition and intervention that is appropriate for the type and grade of irAE. The general management of immune-mediated endocrinopathies differs greatly from the management of other irAEs. Since ICI-mediated endocrine toxicities result in permanent organ damage, management consists of lifelong hormone replacement therapy with continued symptom and laboratory monitoring. Pharmacists are positioned to educate patients in symptom recognition of endocrinopathies to help facilitate rapid diagnosis and appropriate management while allowing for the continuation of ICI therapy. This activity provides an in-depth review of immune-mediated endocrinopathies associated with the use of ICIs and management strategies for oncology pharmacists.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: June 25, 2024
Expiration date: August 25, 2024

Time to complete activity: 1.0 hour

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze the risk factors and unique clinical presentation of immune-mediated endocrinopathies for early identification and management
• Apply unique considerations and interventions specific to endocrine immune-related adverse events (irAEs) to therapeutic decision-making in clinical practice
• Demonstrate effective communication strategies to empower patients to promptly report symptoms of immune-mediated endocrinopathies for a proactive approach to irAE management

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-130-L01-P. The activity is available for CE credit through August 25, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose. 

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms